Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Biguanide Compounds for Estrogen Receptor Positive Breast Cancer Treatment

Technology #20140240

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
CYP3A4BiguanideCYP3A4 Inhibitors
Categories
Researchers
David A. Potter, PhD, MD
Associate Professor, Hematology, Oncology and Transplantation, Department of Medicine
External Link (www.dom.umn.edu)
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

US Patent Pending US20150342909

ER+ Breast Cancer Treatment

Biguanide compounds have been created to treat estrogen receptor positive (ER+) breast cancer. In vitro studies and breast cancer xenograft models showed that these compounds strongly inhibit the activity of CYP3A4, an epoxygenase that promotes cancer cell growth and proliferation in ER+ breast cancer. ER+ breast cancer represents about 75-80% of breast cancer diagnoses and requires estrogen and/or progesterone to grow and metastasize.

CYP3A4 Inhibitors with Hormonal Therapy

Currently, after surgery, chemotherapy or radiation, hormonal therapy is used as an adjuvant treatment to help reduce the risk of cancer recurrence. These CYP3A4 inhibitors could be used in conjunction with hormonal therapy to help decrease the risk of cancer recurrence, or to slow down the progress of metastatic cancer.

At low doses, these inhibitors were found to activate AMPK and to be more potent than Metformin, indicating they could be an effective treatment for type 2 diabetes and to promote weight loss in obese patients.

BENEFITS AND FEATURES OF CYP3A4 INHIBITORS:

  • Could aid hormonal therapies to reduce risk of cancer recurrence or treat metastatic cancer
  • Could be used to treat Type 2 diabetes and to promote weight loss
  • Compounds are potent inhibitors of CYP3A4
  • Activate AMPK

Phase of Development In vivo/animal studies